Sofinnova Partners, a Paris-based venture capital firm, announced today the closure of its sixth fund, Sofinnova Capital VI, bringing in €260 million.
The firm is over 35 years old, and has backed nearly 500 companies; it has around €1 billion of funds under management, an office in San Francisco and an awesome track record.
The investors that fueled the fund include CDC Entreprises, Industrial & Financial Investments Co., JP Morgan Asset Management, funds advised by Partners Group and Skandia Life Insurance Company.
Denis Lucquin, a managing partner of Sofinnova Partners commented “Given the context of the global economy and coupled with our successes during the past 12 months, the closing of our sixth fund is testimony to the fact that our investors recognize our solid investment style and our ability to generate returns, even during turbulent economic times”.
Sofinnova Capital VI will invest in all kind of areas, its former investments (already 
are in healthcare therapeutics, medical devices, green chemistry, wireless and mobile technologies.
The portfolio companies include Celsius, CoAxia, Inc., Crescendo Biologics Ltd, DNP Green Technology, Inc. , Flexion Therapeutics AG, MD Start, Mydeco (UK) and Sagem Wireless (France).
Concluding, Lucquin added: “With the successful trade sales of our portfolio companies and the IPO of Movetis, 2009 confirmed that Sofinnova Partners is a major player in backing entrepreneurs and building world leading technology companies. This to us proves that one can make money with European Venture.”
